Company intelligence / Profile preview

SamGO

Richmond, California, United Statessamgo.io ↗

Ownership: Private
Employees: ~190
Development stage: Other

Overview

Sangamo has advanced multiple programs into clinical development, including hemophilia A and Fabry disease. Its lead programs have shown proof-of-concept in early trials; however, as of March/April 2025, the company’s focus has shifted toward neurology/rare CNS diseases with a strong emphasis on preclinical assets and major pharma partnerships. Some prior late-stage partnered programs have reverted or been deprioritized by partners.

Therapeutic areas: Rare DiseasesHematologyNeurology
Modalities: Gene therapyGene editingCell therapyRNA therapy (gene regulation)Biologic (for some programs)Small molecule (potentially in research tools, but not core pipeline)
Industry: Biotech

Partnerships

Genentech/RochePfizer* (*ended April '25)TakedaAlexion/AstraZenecaLilly/Eli Lilly & Co.Astellas Pharma

Beyond the preview

Go deeper on SamGO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SamGO.

Explore the full profile